Cystic Fibrosis Of The Lung — Patent Landscape
2
Approved drugs
433
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered
Originators in Cystic Fibrosis Of The Lung
Cliff calendar — next 15 years
69
26
114
27
34
28
72
29
58
30
22
31
7
32
54
33
3
35
Approved drugs ranked by patent estate
| Drug | Originator | Active patents | Avg vuln | Revenue | First cliff |
|---|---|---|---|---|---|
|
Kalydeco
IVACAFTOR
|
Vertex Pharms Inc | 425 | 50 | — | 2026-07-06 |
|
Acetadote
Acetylcysteine
|
Bristol-Myers Squibb | 8 | 64 | — | 2031-07-21 |
Most attackable patents
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8722738 | Acetadote | method of use | 73 | 2032-04-06 |
| 8354427 | Kalydeco | method of use | 71 | 2026-07-06 |
| 8354427 | Kalydeco | method of use | 71 | 2026-07-06 |
| 7973038 | Kalydeco | method of use | 71 | 2026-11-08 |
| 8741933 | Kalydeco | method of use | 71 | 2026-11-08 |
| 9670163 | Kalydeco | method of use | 71 | 2026-12-28 |
| 9670163 | Kalydeco | method of use | 71 | 2026-12-28 |
| 9931334 | Kalydeco | method of use | 71 | 2026-12-28 |
| 9670163 | Kalydeco | method of use | 71 | 2026-12-28 |
| 11639347 | Kalydeco | method of use | 71 | 2027-04-09 |
Strongest defences
| Patent | Drug | Type | Vuln | Expiry |
|---|---|---|---|---|
| 8507534 | Kalydeco | composition of matter | 0 | 2030-09-20 |
| 8507534 | Kalydeco | composition of matter | 0 | 2030-09-20 |
| 8507534 | Kalydeco | composition of matter | 0 | 2030-09-20 |
| 8507534 | Kalydeco | composition of matter | 0 | 2030-09-20 |
| 7776905 | Kalydeco | composition of matter | 0 | 2027-06-03 |
| 7776905 | Kalydeco | composition of matter | 0 | 2027-06-03 |
| 7495103 | Kalydeco | composition of matter | 0 | 2027-05-20 |
| 7495103 | Kalydeco | composition of matter | 0 | 2027-05-20 |
| 7495103 | Kalydeco | composition of matter | 0 | 2027-05-20 |
| 7495103 | Kalydeco | composition of matter | 0 | 2027-05-20 |
Related
- Cystic Fibrosis Of The Lung — full disease profile
- AI Patent Landscape Report — type "cystic fibrosis of the lung" for an AI exec memo
- Company Patent Rankings
- Biosimilar Opportunity Scanner